Cevoglitazar

CAS No. 839673-52-8

Cevoglitazar( —— )

Catalog No. M34204 CAS No. 839673-52-8

Cevoglitazar (LBM-642) is a PPARɑ agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 164 Get Quote
5MG 247 Get Quote
10MG 371 Get Quote
25MG 601 Get Quote
50MG 854 Get Quote
100MG 1134 Get Quote
500MG 2277 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cevoglitazar
  • Note
    Research use only, not for human use.
  • Brief Description
    Cevoglitazar (LBM-642) is a PPARɑ agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
  • Description
    Cevoglitazar (LBM-642) is a PPARɑ agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    839673-52-8
  • Formula Weight
    558.53
  • Molecular Formula
    C27H21F3N2O6S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    S(=O)(=O)(N1C=2C(C[C@@H]1C(O)=O)=CC=CC2)C3=CC=C(OCC=4N=C(OC4C)C5=CC=C(C(F)(F)F)C=C5)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • WY-14643 (Pirinixic ...

    WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.

  • MCC 555

    MCC 555 (Isaglitazone;Netoglitazone;RWJ 241947) is an activating ligand of PPARγ with EC50 of 8 uM.

  • CP-868388 free base

    CP-868388 free base (CP-868388) is an orally active, potent and selective PPARα agonist with hypolipidemic and anti-inflammatory activity for the study of dyslipidemia.